Merck, Viatris agree to settle patent feud surrounding diabetes drugs
The dispute between Merck and Viatris over the patent rights for blockbuster diabetes drugs Januvia and Janumet is over — so long as a judge signs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
